{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:05:51Z","timestamp":1783703151351,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2003,3,1]]},"DOI":"10.1038\/sj.bmt.1703896","type":"journal-article","created":{"date-parts":[[2003,3,28]],"date-time":"2003-03-28T13:15:25Z","timestamp":1048857325000},"page":"429-435","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation"],"prefix":"10.1038","volume":"31","author":[{"given":"C","family":"Nilsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Aschan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Hentschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Ringd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Ljungman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2003,3,28]]},"reference":[{"key":"BF1703896_CR1","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1182\/blood.V98.13.3569","volume":"98","author":"G Socie","year":"2001","unstructured":"Socie G, Clift RA, Blaise D et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98: 3569\u20133574.","journal-title":"Blood"},{"key":"BF1703896_CR2","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/sj.bmt.1702371","volume":"25","author":"AM Bolinger","year":"2000","unstructured":"Bolinger AM, Zangwill AB, Slattery JT et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000; 25: 925\u2013930.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703896_CR3","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood.V84.7.2144.2144","volume":"84","author":"M Hassan","year":"1994","unstructured":"Hassan M, Ljungman P, Bolme P et al. Busulfan bioavailability. Blood 1994; 84: 2144\u20132150.","journal-title":"Blood"},{"key":"BF1703896_CR4","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1182\/blood.V82.3.1030.1030","volume":"82","author":"G Vassal","year":"1993","unstructured":"Vassal G, Fischer A, Challine D et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 1993; 82: 1030\u20131034.","journal-title":"Blood"},{"key":"BF1703896_CR5","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood.V79.9.2475.2475","volume":"79","author":"G Vassal","year":"1992","unstructured":"Vassal G, Deroussent A, Challine D et al. Is 600\u2009mg\/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992; 79: 2475\u20132479.","journal-title":"Blood"},{"key":"BF1703896_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF00686213","volume":"33","author":"M Hassan","year":"1993","unstructured":"Hassan M, Oberg G, Bjorkholm M et al. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33: 181\u2013186.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703896_CR7","first-page":"2083","volume":"16","author":"I Buggia","year":"1996","unstructured":"Buggia I, Zecca M, Alessandrino EP et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996; 16: 2083\u20132088.","journal-title":"Anticancer Res"},{"key":"BF1703896_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/00007691-200008000-00003","volume":"22","author":"M Hassan","year":"2000","unstructured":"Hassan M, Svensson JO, Nilsson C et al. Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy. Ther Drug Monit 2000; 22: 383\u2013385.","journal-title":"Ther Drug Monit"},{"key":"BF1703896_CR9","first-page":"18","volume":"20","author":"LB Grochow","year":"1993","unstructured":"Grochow LB . Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20: 18\u201325; quiz 26.","journal-title":"Semin Oncol"},{"key":"BF1703896_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF00688324","volume":"37","author":"G Vassal","year":"1996","unstructured":"Vassal G, Koscielny S, Challine D et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996; 37: 247\u2013253.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF1703896_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0248-8663(88)80137-1","volume":"9","author":"JM Vergnon","year":"1988","unstructured":"Vergnon JM, Boucheron S, Riffat J et al. Interstitial pneumopathies caused by busulfan. Histologic, developmental and bronchoalveolar lavage analysis of 3 cases. Rev Med Intern 1988; 9: 377\u2013383.","journal-title":"Rev Med Intern"},{"key":"BF1703896_CR12","first-page":"869","volume":"15","author":"P Ljungman","year":"1995","unstructured":"Ljungman P, Hassan M, Bekassy AN et al. Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Bone Marrow Transplant 1995; 15: 869\u2013871.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703896_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/sj.bmt.1700891","volume":"20","author":"DS Chattergoon","year":"1997","unstructured":"Chattergoon DS, Saunders EF, Klein J et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children. Bone Marrow Transplant 1997; 20: 347\u2013354.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703896_CR14","first-page":"843","volume":"18","author":"M Hassan","year":"1996","unstructured":"Hassan M, Fasth A, Gerritsen B et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996; 18: 843\u2013850.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703896_CR15","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/sj.bmt.1701745","volume":"23","author":"AR Zander","year":"1999","unstructured":"Zander AR, Zabelina T, Kroger N et al. Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplant 1999; 23: 889\u2013893.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703896_CR16","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1182\/blood.V93.10.3267.410k22_3267_3275","volume":"93","author":"DW Beelen","year":"1999","unstructured":"Beelen DW, Elmaagacli A, Muller KD et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 1999; 93: 3267\u20133275.","journal-title":"Blood"},{"key":"BF1703896_CR17","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1128\/AAC.43.7.1533","volume":"43","author":"J Samuelson","year":"1999","unstructured":"Samuelson J . Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother 1999; 43: 1533\u20131541.","journal-title":"Antimicrob Agents Chemother"},{"key":"BF1703896_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJM198603203141201","volume":"314","author":"R Storb","year":"1986","unstructured":"Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow trans-plantation for leukemia. N Engl J Med 1986; 314: 729\u2013735.","journal-title":"N Engl J Med"},{"key":"BF1703896_CR19","first-page":"619","volume":"15","author":"O Ringden","year":"1995","unstructured":"Ringden O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619\u2013625.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703896_CR20","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/S0378-4347(00)84861-6","volume":"277","author":"M Hassan","year":"1983","unstructured":"Hassan M, Ehrsson H . Gas chromatographic determination of busulfan in plasma with electron-capture detection. J Chromatogr 1983; 277: 374\u2013380.","journal-title":"J Chromatogr"},{"key":"BF1703896_CR21","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","volume":"44","author":"RJ Jones","year":"1987","unstructured":"Jones RJ, Lee KS, Beschorner WE et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778\u2013783.","journal-title":"Transplantation"},{"key":"BF1703896_CR22","first-page":"6203","volume":"50","author":"G Vassal","year":"1990","unstructured":"Vassal G, Deroussent A, Hartmann O et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990; 50: 6203\u20136207.","journal-title":"Cancer Res"},{"key":"BF1703896_CR23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/sj.bmt.1702823","volume":"27","author":"Z Hassan","year":"2001","unstructured":"Hassan Z, Ljungman P, Ringden O et al. Pharmacokinetics of liposomal busulphan in man. Bone Marrow Transplant 2001; 27: 479\u2013485.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703896_CR24","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/sj.leu.2401921","volume":"14","author":"E Olavarria","year":"2000","unstructured":"Olavarria E, Hassan M, Eades A et al. A phase I\/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia 2000; 14: 1954\u20131959.","journal-title":"Leukemia"},{"key":"BF1703896_CR25","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S1083-8791(00)70064-4","volume":"6","author":"BS Andersson","year":"2000","unstructured":"Andersson BS, Madden T, Tran HT et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000; 6: 548\u2013554.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BF1703896_CR26","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1046\/j.1365-2141.2001.03044.x","volume":"114","author":"US Schuler","year":"2001","unstructured":"Schuler US, Renner UD, Kroschinsky F et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 2001; 114: 944\u2013950.","journal-title":"Br J Haematol"},{"key":"BF1703896_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0773.1990.tb01611.x","volume":"66","author":"S Loft","year":"1990","unstructured":"Loft S . Metronidazole and antipyrine as probes for the study of foreign compound metabolism. Pharmacol Toxicol 1990; 66: 1\u201331.","journal-title":"Pharmacol Toxicol"},{"key":"BF1703896_CR28","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1111\/j.1528-1157.1995.tb06007.x","volume":"36","author":"RH Levy","year":"1995","unstructured":"Levy RH . Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995; 36: S8\u2013S13.","journal-title":"Epilepsia"},{"key":"BF1703896_CR29","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/0006-2952(89)90259-1","volume":"38","author":"S Loft","year":"1989","unstructured":"Loft S, Poulsen HE . Metabolism of metronidazole and antipyrine in isolated rat hepatocytes. Influence of sex and enzyme induction and inhibition. Biochem Pharmacol 1989; 38: 1125\u20131136.","journal-title":"Biochem Pharmacol"},{"key":"BF1703896_CR30","first-page":"782","volume":"51","author":"FJ Kazmier","year":"1976","unstructured":"Kazmier FJ . A significant interaction between metronidazole and warfarin. Mayo Clin Proc 1976; 51: 782\u2013784.","journal-title":"Mayo Clin Proc"},{"key":"BF1703896_CR31","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/00008571-200106000-00002","volume":"11","author":"J van der Weide","year":"2001","unstructured":"van der Weide J, Steijns LS, van Weelden MJ et al. The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement. Pharmacogenetics 2001; 11: 287\u2013291.","journal-title":"Pharmacogenetics"},{"key":"BF1703896_CR32","doi-asserted-by":"publisher","first-page":"198","DOI":"10.2165\/00003088-199631030-00004","volume":"31","author":"E Spina","year":"1996","unstructured":"Spina E, Pisani F, Perucca E . Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996; 31: 198\u2013214.","journal-title":"Clin Pharmacokinet"},{"key":"BF1703896_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/BF03189864","volume":"12","author":"M Hassan","year":"1987","unstructured":"Hassan M, Ehrsson H . Metabolism of 14C-busulfan in isolated perfused rat liver. Eur J Drug Metab Pharmacokinet 1987; 12: 71\u201376.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"BF1703896_CR34","first-page":"85","volume":"16","author":"DH Marchand","year":"1988","unstructured":"Marchand DH, Remmel RP, Abdel-Monem MM . Biliary excretion of a glutathione conjugate of busulfan and 1,4-diiodobutane in the rat. Drug Metab Dispos 1988; 16: 85\u201392.","journal-title":"Drug Metab Dispos"},{"key":"BF1703896_CR35","first-page":"52","volume":"26","author":"JP Gibbs","year":"1998","unstructured":"Gibbs JP, Yang JS, Slattery JT . Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro. Drug Metab Dispos 1998; 26: 52\u201355.","journal-title":"Drug Metab Dispos"},{"key":"BF1703896_CR36","first-page":"5509","volume":"57","author":"JP Gibbs","year":"1997","unstructured":"Gibbs JP, Murray G, Risler L et al. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 1997; 57: 5509\u20135516.","journal-title":"Cancer Res"},{"key":"BF1703896_CR37","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/BF00558081","volume":"36","author":"M Hassan","year":"1989","unstructured":"Hassan M, Oberg G, Ehrsson H et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36: 525\u2013530.","journal-title":"Eur J Clin Pharmacol"},{"key":"BF1703896_CR38","first-page":"399","volume":"15","author":"M Hassan","year":"1987","unstructured":"Hassan M, Ehrsson H . Urinary metabolites of busulfan in the rat. Drug Metab Dispos 1987; 15: 399\u2013402.","journal-title":"Drug Metab Dispos"},{"key":"BF1703896_CR39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1515\/DMDI.1988.6.3-4.235","volume":"6","author":"LA Damani","year":"1988","unstructured":"Damani LA, Houdi AA . Cytochrome P-450 and FAD-monooxygenase mediated S- and N-oxygenations. Drug Metabol Drug Interact 1988; 6: 235\u2013244.","journal-title":"Drug Metabol Drug Interact"},{"key":"BF1703896_CR40","first-page":"667","volume":"249","author":"AJ Sherratt","year":"1989","unstructured":"Sherratt AJ, Banet DE, Linder MW et al. Potentiation of 3-methylcholanthrene induction of rat hepatic cytochrome P450IA1 by dexamethasone in vivo. J Pharmacol Exp Ther 1989; 249: 667\u2013672.","journal-title":"J Pharmacol Exp Ther"},{"key":"BF1703896_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1600-0773.1997.tb00033.x","volume":"81","author":"P Larsson","year":"1997","unstructured":"Larsson P, Cybulski W, Tjalve H . Binding of 3H-metronidazole in olfactory, respiratory and alimentary epithelia in rats. Pharmacol Toxicol 1997; 81: 65\u201373.","journal-title":"Pharmacol Toxicol"},{"key":"BF1703896_CR42","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1600-0773.1990.tb00758.x","volume":"66","author":"A Martelli","year":"1990","unstructured":"Martelli A, Allavena A, Robbiano L et al. Comparison of the sensitivity of human and rat hepatocytes to the geno-toxic effects of metronidazole. Pharmacol Toxicol 1990; 66: 329\u2013334.","journal-title":"Pharmacol Toxicol"},{"key":"BF1703896_CR43","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/sj.bmt.1702377","volume":"25","author":"M Hassan","year":"2000","unstructured":"Hassan M, Ljungman P, Ringden O et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915\u2013924.","journal-title":"Bone Marrow Transplant"},{"key":"BF1703896_CR44","first-page":"114","volume":"126","author":"HM Shulman","year":"1987","unstructured":"Shulman HM, Luk K, Deeg HJ et al. Induction of hepatic veno-occlusive disease in dogs. Am J Pathol 1987; 126: 114\u2013125.","journal-title":"Am J Pathol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703896","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703896.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703896.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T10:34:36Z","timestamp":1704796476000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,1]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,3,1]]}},"alternative-id":["BF1703896"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703896","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3,1]]},"assertion":[{"value":"14 March 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}